Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

October 30, 2019October 30, 2019

Lynparza-Avastin First-Line Maintenance Therapy Delays Cancer Progression in Advanced OC, Phase 3 Study Shows

News

Adding Lynparza (olaparib) to Avastin (bevacizumab) as a first-line maintenance treatment significantly delayed disease progression in women with advanced ovarian cancer — regardless of BRCA mutation status — interim data from a Phase ... Read more

October 9, 2019

Navicixizumab Earns FDA Fast Track Designation for Heavily Pretreated Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to navicixizumab (OMP-305B83) as a potential therapy for heavily pretreated ovarian cancer, Mereo BioPharma, the therapy’s developer, announced. Fast track ... Read more

October 7, 2019October 7, 2019

Mirvetuximab Soravtansine Effectively Delays Disease Progression in FRα-high Ovarian Cancers, Analysis Finds

News

ImmunoGen’s investigational therapy mirvetuximab soravtansine effectively delays disease progression in women with ovarian cancer who have high levels of the folate receptor alpha (FRα) protein, compared with chemotherapy, according to ... Read more

October 2, 2019October 3, 2019

Gynecological Cancer Patients with Specific Wnt Mutations and High DKK1 Levels Respond Better to DKN-01, Trial Results Show

News

Leap Therapeutics’s investigational therapy DKN-01, alone or in combination with Taxol (paclitaxel), leads to significantly better responses in women with relapsed endometrial or ovarian cancer whose tumors have high levels of the Dickkopf-1 ... Read more

September 6, 2019September 6, 2019

Ampligen Combo Safe, Effective in Treating Recurrent Ovarian Cancer, Phase 1 Study Shows

News

A combination of Hemispherx Biopharma‘s investigational treatment Ampligen (rintatolimod) with chemo-immunotherapy is safe and effective in treating women with recurrent ovarian cancer, according to the final report of a Phase ... Read more

August 30, 2019September 4, 2019

Research into Tumor Suppressor P53 in Ovarian Cancer Receives $1.8M NIH Grant

News

A research team at the David Geffen School of Medicine at UCLA received a $1.8 million, five-year grant from the National Institutes of Health (NIH) to develop new therapeutic and ... Read more

November 2, 2018

Compugen, Bristol-Myers Squibb Collaborating to Test COM701, Opdivo Combo for Ovarian, Other Cancers

News

Compugen has entered into a clinical trial collaboration with Bristol-Myers Squibb (BMS) to evaluate the safety and preliminary effectiveness of its investigational immunotherapy COM701 in combination with BMS’ Opdivo (nivolumab), in a ... Read more

October 17, 2018

Carrick Acquires Rights to CT900, Plans New Trial in Ovarian Cancer Patients

News

Carrick Therapeutics, a biopharmaceutical company, has acquired the rights to CT900 and plans to conduct a later-stage clinical trial to evaluate the safety and effectiveness of the investigational therapy in ... Read more

October 1, 2018

Extracellular Matrix Changes in Ovarian Cancer Focus of 5-Year Study at University of Wisconsin-Madison

News

Researchers at University of Wisconsin–Madison were awarded a $2.2 million, five-year grant to study the changes that occur in the extracellular matrix — a network of molecules in which cells ... Read more

July 30, 2018

Loss of Certain Protein Identified in Ovarian Cancer Resistance to PARP Inhibitors

News

Researchers have identified a mechanism of resistance to PARP inhibitors — such as Lynparza (olaparib) and — in ovarian cancer, that involves the loss of a specific protein called 53BP1, according to ... Read more